argenx SE (NASDAQ:ARGX) Holdings Lowered by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. lowered its holdings in argenx SE (NASDAQ:ARGX - Free Report) by 16.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,147 shares of the company's stock after selling 1,753 shares during the period. Polar Asset Management Partners Inc.'s holdings in argenx were worth $4,958,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. J.Safra Asset Management Corp lifted its position in shares of argenx by 590.0% during the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company's stock worth $30,000 after purchasing an additional 59 shares in the last quarter. Blue Trust Inc. grew its stake in shares of argenx by 620.0% during the second quarter. Blue Trust Inc. now owns 72 shares of the company's stock valued at $28,000 after acquiring an additional 62 shares in the last quarter. GAMMA Investing LLC increased its position in shares of argenx by 51.3% during the second quarter. GAMMA Investing LLC now owns 118 shares of the company's stock worth $51,000 after acquiring an additional 40 shares during the last quarter. Cromwell Holdings LLC lifted its stake in shares of argenx by 73.3% in the third quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock worth $85,000 after acquiring an additional 66 shares in the last quarter. Finally, Point72 Hong Kong Ltd purchased a new position in argenx in the second quarter valued at about $76,000. Hedge funds and other institutional investors own 60.32% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ARGX shares. HC Wainwright restated a "buy" rating and set a $617.00 price objective on shares of argenx in a report on Wednesday, November 20th. Citigroup lifted their price target on shares of argenx from $512.00 to $635.00 and gave the stock a "buy" rating in a research note on Thursday, October 17th. Baird R W cut shares of argenx from a "strong-buy" rating to a "hold" rating in a report on Friday, November 1st. Scotiabank raised shares of argenx from a "sector perform" rating to a "sector outperform" rating and raised their price objective for the stock from $439.00 to $715.00 in a report on Tuesday, November 5th. Finally, JMP Securities boosted their target price on shares of argenx from $497.00 to $606.00 and gave the stock a "market outperform" rating in a research report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, argenx currently has an average rating of "Moderate Buy" and an average price target of $635.42.

argenx Stock Performance

Shares of ARGX stock traded up $1.16 during mid-day trading on Thursday, hitting $626.12. 194,885 shares of the stock traded hands, compared to its average volume of 309,734. argenx SE has a twelve month low of $327.73 and a twelve month high of $630.00. The company's 50-day simple moving average is $572.79 and its 200-day simple moving average is $503.18. The firm has a market cap of $37.80 billion, a price-to-earnings ratio of -711.50 and a beta of 0.59.

argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. During the same period in the previous year, the company earned ($1.25) earnings per share. Analysts forecast that argenx SE will post 2.2 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.